New potential weapons for refractory scleritis in the era of targeted therapy
| العنوان: | New potential weapons for refractory scleritis in the era of targeted therapy |
|---|---|
| المؤلفون: | Lorenzo Vannozzi, José Hernández-Rodríguez, Maite Sainz-de-la-Maza, Claudia Fabiani, Giacomo Emmi, Florenzo Iannone, Giuseppe Lopalco, Donato Rigante, Maria Chiara Gelmi, Silvana Guerriero, Jurgen Sota, Laura Pelegrín, Gian Marco Tosi, Luca Cantarini |
| المصدر: | Mediators of Inflammation Mediators of Inflammation, Vol 2020 (2020) Dipòsit Digital de la UB Universidad de Barcelona |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Drug targeting, Male, Settore MED/16 - REUMATOLOGIA, medicine.medical_treatment, Targeted therapy, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Agents, Immunological, Piperidines, Recurrence, Pathology, RB1-214, Middle Aged, Inflamació, Dianes farmacològiques, Treatment Outcome, Rituximab, Female, medicine.drug, Research Article, Adult, medicine.medical_specialty, Article Subject, Immunology, Antibodies, Monoclonal, Humanized, Assaigs clínics de medicaments, Abatacept, 03 medical and health sciences, Tocilizumab, Internal medicine, medicine, Humans, Adverse effect, Aged, Retrospective Studies, 030203 arthritis & rheumatology, Inflammation, Anakinra, Tofacitinib, business.industry, Drug testing, Cell Biology, medicine.disease, Interleukin 1 Receptor Antagonist Protein, Ophthalmology, Pyrimidines, chemistry, Immune System, 030221 ophthalmology & optometry, business, Scleritis |
| الوصف: | Objective. To assess the efficacy of biologic drugs, beyond tumor necrosis factor- (TNF-) α inhibitors, in the management of noninfectious refractory scleritis, either idiopathic or associated with systemic immune-mediated disorders. Patients and Methods. This is a retrospective study assessing the efficacy of several biologic agents (rituximab, anakinra, tocilizumab, and abatacept) and the small molecule tofacitinib in the treatment of scleritis through assessment of scleral inflammation and relapses, as well as treatment impact on best-corrected visual acuity (BCVA) and safety profile. Results. Fourteen patients (19 eyes) were enrolled in the study. Scleritis inflammatory grading significantly improved from baseline to 3 months (p=0.002) and from baseline to the last follow-up visit (p=0.002). Scleritis relapses significantly decreased between the 12 months preceding and following biologic therapy (p=0.007). No differences regarding BCVA were observed (p=0.67). Regarding adverse events, only one patient developed pneumonia and septic shock under rituximab treatment. Conclusions. Our results, though limited to a low number of patients, highlight the effectiveness of different biologic therapies in the treatment of noninfectious refractory scleritis, showing to control scleral inflammation and allowing a significant reduction in the number of relapses. |
| وصف الملف: | application/pdf; text/xhtml |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7e9b0e665d3fb6519e52363aa36302dTest http://hdl.handle.net/11365/1123825Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e7e9b0e665d3fb6519e52363aa36302d |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |